#1 Clinical Trials Search in Europe

Cldn6 Rna-Lpx

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of a new drug called CLDN6 RNA-LPX, used in combination with CLDN6 CAR-T cell therapy. This study focuses on patients with advanced solid tumors that have not responded to other treatments. The trial aims to assess how well this innovative approach works and if it can provide new hope for patients with difficult-to-treat cancers.

Table of Contents

What is CLDN6 RNA-LPX?

CLDN6 RNA-LPX is an investigational treatment being developed for advanced solid tumors. It is a type of RNA-based vaccine that is delivered in a special formulation called liposomal formulation (LPX)[1]. This treatment is part of a broader approach that combines it with another therapy called CLDN6 CAR-T.

How Does It Work?

CLDN6 RNA-LPX works by targeting a specific protein called Claudin 6 (CLDN6). This protein is found on the surface of certain cancer cells. The treatment is designed to stimulate the body’s immune system to recognize and attack cancer cells that express this protein[1].

When used in combination with CLDN6 CAR-T therapy, it may enhance the overall anti-tumor response. CAR-T therapy involves modifying a patient’s own T cells (a type of immune cell) to target and destroy cancer cells more effectively[1].

Target Conditions

CLDN6 RNA-LPX is being investigated for the treatment of several types of advanced solid tumors, including:

  • Malignant solid tumors: These are cancers that form solid masses in various organs[1].
  • Carcinoma of unknown primary: A type of cancer where the original site of the tumor is not known[1].
  • Testicular cancer: Cancer that develops in the testicles[1].
  • Non-small cell lung cancer: A common type of lung cancer[1].

Clinical Trial Details

CLDN6 RNA-LPX is currently being studied in a Phase I/IIa clinical trial. This is a first-in-human study, which means it’s the first time this treatment is being tested in people. The trial aims to evaluate the safety and effectiveness of CLDN6 CAR-T therapy with or without CLDN6 RNA-LPX in patients with CLDN6-positive advanced solid tumors[1].

Eligibility Criteria

To participate in the trial, patients must meet certain criteria, including:

  • Having a CLDN6-positive tumor, regardless of the type of tumor[1].
  • Being 18 years of age or older[1].
  • Having adequate organ function (blood, liver, kidney)[1].
  • Having a cancer that is metastatic (spread to other parts of the body) or cannot be surgically removed[1].

Potential Benefits

While it’s important to note that the effectiveness of CLDN6 RNA-LPX is still being studied, the potential benefits being investigated include:

  • Possible anti-tumor activity against CLDN6-positive solid tumors[1].
  • A new treatment option for patients who have exhausted standard therapies[1].
  • Potential to enhance the effectiveness of CLDN6 CAR-T therapy when used in combination[1].

Safety Considerations

As with any investigational treatment, there are potential risks and side effects. The clinical trial is designed to carefully monitor and assess these, including:

  • Occurrence of treatment-related side effects[1].
  • Monitoring for serious or life-threatening reactions[1].
  • Evaluation of dose-limiting toxicities (side effects that are severe enough to prevent increasing the dose)[1].

It’s crucial for patients to discuss potential risks and benefits with their healthcare providers before considering participation in any clinical trial.

Aspect Details
Study Type Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts
Main Objective Assess safety and tolerability of CLDN6 CAR-T ± CLDN6 RNA-LPX
Target Conditions CLDN6-positive relapsed or refractory advanced solid tumors
Key Eligibility Criteria ≥18 years old, CLDN6-positive tumor, adequate organ function, no standard therapy options
Primary Endpoints Occurrence of treatment-emergent adverse events, dose-limiting toxicities
Secondary Endpoints Changes in immune factors, objective response rate, duration of response
Follow-up Period At least 12 months after treatment

FAQ

  • What is CLDN6 RNA-LPX? CLDN6 RNA-LPX is an investigational RNA-based vaccine that targets a specific protein called claudin 6 (CLDN6), which is found in certain types of cancer cells. It is being studied in combination with a cell therapy called CLDN6 CAR-T to treat advanced solid tumors.
  • What types of cancers are being studied in this trial? The trial is focusing on various types of advanced solid tumors, including malignant solid tumors, carcinoma of unknown primary, testicular cancer, and non-small cell lung cancer. The study is particularly interested in tumors that express the CLDN6 protein.
  • Who is eligible to participate in this clinical trial? Eligible participants must be 18 years or older, have a CLDN6-positive tumor, adequate organ function, and have exhausted standard treatment options or be unsuitable for available therapies. They must also meet specific criteria regarding tumor measurability and tissue sample availability.
  • What are the main goals of this clinical trial? The primary objectives are to assess the safety and tolerability of CLDN6 CAR-T therapy with or without CLDN6 RNA-LPX, and to evaluate the comparability of CLDN6 CAR-T from manual and automated processes. Secondary goals include studying immune responses and measuring anti-tumor activity.
  • How long will participants need to be monitored after receiving treatment? Participants will need to be monitored for at least 12 months after receiving the CLDN6 CAR-T infusion or CLDN6 RNA-LPX treatment. During this time, they must agree to use effective birth control methods and not to donate eggs or sperm.

Ongoing Clinical Trials on Cldn6 Rna-Lpx

  • A Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany The Netherlands Sweden

Glossary

  • CLDN6 RNA-LPX: An investigational RNA-based vaccine that targets the claudin 6 (CLDN6) protein, which is found in certain types of cancer cells.
  • CAR-T therapy: A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.
  • Solid tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer) or malignant (cancer).
  • Immunohistochemistry (IHC): A lab test that uses antibodies to check for certain antigens (markers) in a sample of tissue. It is often used to help diagnose cancer and determine the best treatment options.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a set of rules used to measure how well a cancer patient responds to treatment.
  • Dose-limiting toxicity (DLT): Side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Duration of response (DOR): The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cldn6-car-t-and-cldn6-rna-lpx-in-patients-with-advanced-solid-tumors/